GSK’s perpetual asthma inhaler updates have kept generics makers chasing a moving target for more than half a century, and it’s patients who are being forced to foot the bill, a new lawsuit filed in a ...

One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially leaving patients, healthcare providers and insurers scrambling.

A popular corticosteroid inhaler used to treat asthma and other conditions is being discontinued, and despite generic versions now available, health experts are warning patients to plan ahead for ...

Missouri resident Elliot Conrad Dale recently filed an antitrust lawsuit against GlaxoSmithKline (“GSK”), claiming GSK employed a “device hopping” scheme to ensure uninterrupted patent and regulatory ...

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...

After Flovent, one of the most popular inhalers for treating childhood asthma, was discontinued this past January, some parents are reporting challenges in obtaining the generic versions of the ...

If you have not heard already, one of the most popular inhalers has been discontinued by its manufacturer since January 1. GlaxoSmithKline (GSK) has stopped producing Flovent, which comes as a metered ...

People using the popular corticosteroid inhalers Flovent HFA or Flovent Diskus to treat their asthma will need to switch to a new product in 2024. Flovent manufacturer GlaxoSmithKline announced in ...